Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03762590 · ClinicalTrials.gov registry record · NA
GENetic Education Risk Assessment and TEsting Study
A NA study of Candidates for Hereditary Pancreatic Cancer Testing, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT03762590: Active NA study of Candidates for Hereditary Pancreatic Cancer Testing, sponsored by Dana-Farber Cancer Institute.
NCT03762590 is a NA study of Candidates for Hereditary Pancreatic Cancer Testing that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03762590, a NA study of Candidates for Hereditary Pancreatic Cancer Testing, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the GENERATE Study is to improve genetic testing and cancer prevention in family members of pancreatic cancer patients who may have genetic mutations (inherited changes). The study will measure how different methods of genetic education increase the rate of genetic testing in these families. This is an investigational study to measure the effects of two methods of genetic education. Participants may elect to undergo genetic testing as part of the study and will be asked to provide a saliva sample via a saliva-testing kit. The genetic testing done in this study is FDA approved and will be processed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Up to 1,000 participants will be enrolled in this study.
Primary Outcome
Measure the effect that alternative methods of genetic education and delivery models have on the increase of genetic testing among family members of mutation positive PDAC patients, among family members of mutation positive individuals with a family history of PDAC and among first-degree relatives of PDAC patients in each arm of the intervention study. We will document how many relatives per family elect to undergo genetic testing and compare the results of this measure between both arms of the
Conditions Studied
Interventions
- OTHER Doxy.me genetic education +/- Color Genomics genetic education
- OTHER Color Genomics genetic education
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What the registry record for NCT03762590 still lists
NCT03762590 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Candidates for Hereditary Pancreatic Cancer Testing appearing as the primary indexed condition, and to 2 interventions - of which Doxy.me genetic education +/- Color Genomics genetic education is the first listed.
NCT03762590 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03762590 about?
NCT03762590 is a clinical study titled "GENetic Education Risk Assessment and TEsting Study". The goal of the GENERATE Study is to improve genetic testing and cancer prevention in family members of pancreatic cancer patients who may have genetic mutations (inherited changes). The study will measure how different methods of genetic education increase the rate of genetic testing in these famil...
What is the current status of trial NCT03762590?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2019-05-08. Estimated completion is 2027-12-31.
What conditions does trial NCT03762590 study?
This clinical trial studies the following conditions: Candidates for Hereditary Pancreatic Cancer Testing.
What interventions are being tested in trial NCT03762590?
The interventions under investigation include: Doxy.me genetic education +/- Color Genomics genetic education (OTHER), Color Genomics genetic education (OTHER).
Who is sponsoring clinical trial NCT03762590?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03762590 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03762590's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI